Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Sees Large Increase in Short Interest

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the recipient of a large increase in short interest during the month of August. As of August 31st, there was short interest totalling 364,200 shares, an increase of 398.9% from the August 15th total of 73,000 shares. Based on an average daily trading volume, of 380,200 shares, the short-interest ratio is presently 1.0 days. Approximately 5.4% of the company’s stock are short sold.

Wall Street Analyst Weigh In

Separately, HC Wainwright reiterated a “buy” rating on shares of Kiora Pharmaceuticals in a research note on Thursday, August 24th.

Kiora Pharmaceuticals Price Performance

KPRX stock opened at $0.53 on Friday. Kiora Pharmaceuticals has a 52-week low of $0.46 and a 52-week high of $10.39. The company’s 50-day simple moving average is $0.56 and its 200-day simple moving average is $1.91.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of KPRX. Boothbay Fund Management LLC acquired a new position in Kiora Pharmaceuticals during the fourth quarter worth about $40,000. Dimensional Fund Advisors LP purchased a new position in Kiora Pharmaceuticals in the 1st quarter worth approximately $41,000. Acadian Asset Management LLC acquired a new position in shares of Kiora Pharmaceuticals during the 1st quarter worth approximately $70,000. Renaissance Technologies LLC acquired a new position in shares of Kiora Pharmaceuticals during the 1st quarter worth approximately $58,000. Finally, Walleye Capital LLC purchased a new stake in shares of Kiora Pharmaceuticals in the second quarter valued at approximately $162,000. Institutional investors and hedge funds own 13.92% of the company’s stock.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.